A shelf registration statement relating to this offering was filed with the
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About
Contact:
Aclaris Contact
Senior Vice President
Corporate Strategy/Investor Relations
484-329-2140
mtung@aclaristx.com
Media Contact
Vice President, Corporate Communications
484-321-5559
media@aclaristx.com
Source: Aclaris Therapeutics, Inc.